General Information of Drug Combination (ID: DCFLQAD)

Drug Combination Name
Vinflunine Hepzato
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs Vinflunine   DMTJAEP Hepzato   DM2AZPP
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: MCF7
Zero Interaction Potency (ZIP) Score: 0.66
Bliss Independence Score: 2.59
Loewe Additivity Score: 1.79
LHighest Single Agent (HSA) Score: 0.82

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCASY1N HL-60(TB) Investigative [4]
Adenocarcinoma DCLOPGX HT29 Investigative [5]
Adenocarcinoma DCBFZHO HCT-15 Investigative [5]
High grade ovarian serous adenocarcinoma DC9X6C6 OVCAR-5 Investigative [5]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.